2023-508662-15-00招募中1 期
RIVKAL clinical trial for the first-in-human administration of BIM2b in participants with Glioblastoma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Beta Innov
- 入组人数
- 36
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Beta Innov
Scientific
Beta Innov
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid TumorsNCT07265921Jiangsu Simcere Pharmaceutical Co., Ltd.232
招募中
1 期
A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and its Anti-tumour Effect in Adult Patients with CD44v6 Expressing Solid Tumours2023-508126-95-00Karolinska University Hospital30
招募中
1 期
First in human clinical trial to evaluate the safety, tolerability and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer2022-503084-15-00Deutsches Krebsforschungszentrum (DKFZ)77
招募中
1 期
A Study of DB-1324 in Advanced/Metastatic Gastrointestinal TumorsNCT07263594DualityBio Inc.127
招募中
1 期
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) TumorsNCT07262619Eikon Therapeutics160